Abstract
Background: Persistent oxidative stress may play a key role in microvascular obstruction (MVO). We aimed at assessing the role of platelet gp91phox (NOX2), the catalytic subunit of NADPH oxidase in MVO. Methods: We enrolled 40 patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention within 12 h from symptoms onset, either with angiographic MVO (n=20) or good angiographic myocardial reperfusion (MR) (n=20). Angiographic MVO was defined as a final thrombolysis in myocardial infarction (TIMI) flow ≤2 or TIMI flow of 3 with myocardial blush grade 2α showed a trend to increase from baseline to pre-discharge in angiographic MVO patients (295 (183.50-389.25) pmol/l vs 322 (206-370) pmol/l, p=0.06), but not in patients with MR (p=0.56), with a trend for interaction between baseline and pre-discharge levels among the two groups (p=0.09). Conclusion: Patients with MVO, but not those with myocardial reperfusion, have a sustained increase of NOX2 and 8-iso-PGF2α. Therapies targeting NOX2 or high dosage antioxidants should be tested for MVO prevention and treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 379-388 |
| Number of pages | 10 |
| Journal | European Heart Journal: Acute Cardiovascular Care |
| Volume | 2 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2013 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Critical Care and Intensive Care Medicine
Cite this
Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion. / Niccoli, Giampaolo; Celestini, Andrea; Calvieri, Camilla; Cosentino, Nicola; Falcioni, Elena; Carnevale, Roberto; Nocella, Cristina; Fracassi, Francesco; Roberto, Marco; Antonazzo, Roberta P.; Pignatelli, Pasquale; Crea, Filippo; Violi, Francesco.
In: European Heart Journal: Acute Cardiovascular Care, Vol. 2, No. 4, 2013, p. 379-388.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion
AU - Niccoli, Giampaolo
AU - Celestini, Andrea
AU - Calvieri, Camilla
AU - Cosentino, Nicola
AU - Falcioni, Elena
AU - Carnevale, Roberto
AU - Nocella, Cristina
AU - Fracassi, Francesco
AU - Roberto, Marco
AU - Antonazzo, Roberta P.
AU - Pignatelli, Pasquale
AU - Crea, Filippo
AU - Violi, Francesco
PY - 2013
Y1 - 2013
N2 - Background: Persistent oxidative stress may play a key role in microvascular obstruction (MVO). We aimed at assessing the role of platelet gp91phox (NOX2), the catalytic subunit of NADPH oxidase in MVO. Methods: We enrolled 40 patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention within 12 h from symptoms onset, either with angiographic MVO (n=20) or good angiographic myocardial reperfusion (MR) (n=20). Angiographic MVO was defined as a final thrombolysis in myocardial infarction (TIMI) flow ≤2 or TIMI flow of 3 with myocardial blush grade 2α showed a trend to increase from baseline to pre-discharge in angiographic MVO patients (295 (183.50-389.25) pmol/l vs 322 (206-370) pmol/l, p=0.06), but not in patients with MR (p=0.56), with a trend for interaction between baseline and pre-discharge levels among the two groups (p=0.09). Conclusion: Patients with MVO, but not those with myocardial reperfusion, have a sustained increase of NOX2 and 8-iso-PGF2α. Therapies targeting NOX2 or high dosage antioxidants should be tested for MVO prevention and treatment.
AB - Background: Persistent oxidative stress may play a key role in microvascular obstruction (MVO). We aimed at assessing the role of platelet gp91phox (NOX2), the catalytic subunit of NADPH oxidase in MVO. Methods: We enrolled 40 patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention within 12 h from symptoms onset, either with angiographic MVO (n=20) or good angiographic myocardial reperfusion (MR) (n=20). Angiographic MVO was defined as a final thrombolysis in myocardial infarction (TIMI) flow ≤2 or TIMI flow of 3 with myocardial blush grade 2α showed a trend to increase from baseline to pre-discharge in angiographic MVO patients (295 (183.50-389.25) pmol/l vs 322 (206-370) pmol/l, p=0.06), but not in patients with MR (p=0.56), with a trend for interaction between baseline and pre-discharge levels among the two groups (p=0.09). Conclusion: Patients with MVO, but not those with myocardial reperfusion, have a sustained increase of NOX2 and 8-iso-PGF2α. Therapies targeting NOX2 or high dosage antioxidants should be tested for MVO prevention and treatment.
UR - http://www.scopus.com/inward/record.url?scp=84906908543&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906908543&partnerID=8YFLogxK
U2 - 10.1177/2048872613504698
DO - 10.1177/2048872613504698
M3 - Article
C2 - 24338297
AN - SCOPUS:84906908543
VL - 2
SP - 379
EP - 388
JO - European Heart Journal: Acute Cardiovascular Care
JF - European Heart Journal: Acute Cardiovascular Care
SN - 2048-8726
IS - 4
ER -